Therapeutic Pipeline Investment aims to Reduce Developmental Risk
May 02 2021 Read 9 Times An investment of €1M ($1.2M) in a new pipeline of complex therapeutic targets and native antigens of high relevance for pharmaceutical companies has been announced by French biotech Calixar. This strategic investment, supported by Bpifrance investment bank, will enable the company to provide native and functional membrane therapeutic targets (GPCRs, ion channels, transporters, receptors and viral targets) and advance drugs and vaccines developments. “Collective studies agree that the pharmaceutical industry needs to optimise its drug development model,” said Emm...